Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2126 - 2150 of 15111 in total
Brivudine is used in the treatment of herpes zoster. Although not approved in the U.S. or Canada, it is approved in several European countries.
Approved
Investigational
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides ... Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors …
Erdosteine is a drug that causes a breakdown of mucus, also known as a mucolytic agent. It is a thiol derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic bronchitis. This drug contains sulfhydryl groups which are released after erdosteine undergoes hepatic...
Approved
Investigational
Matched Iupac: … 2-({[(2-oxothiolan-3-yl)carbamoyl]methyl}sulfanyl)acetic acid
Matched Description: … and more effectively than placebo and reduced the adhesivity of sputum more effectively than ambroxol ... Erdosteine 300mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly ... Erdosteine has been shown to be safe and well tolerated in clinical trials. …
Matched Categories: … Cough and Cold Preparations …
Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.
Approved
Investigational
Matched Iupac: … 2-[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanamido]acetic acid
Matched Description: … It is used to avoid postoperative ileus following small or large bowel resection and accelerates the …
Matched Categories: … Alimentary Tract and Metabolism …
Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete Streptomyces puniceus.
Approved
Matched Description: … These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
Approved
Withdrawn
Matched Iupac: … [3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Approved
Matched Iupac: … (2S)-2-amino-4-[methyl(⁷⁵Se)selanyl]butanoic acid
Matched Categories: … Amino Acids, Peptides, and Proteins …
Magnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency.
Approved
Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell leukemia....
Approved
Investigational
Matched Description: … Cladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and ... [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Approved
Matched Description: … It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
An alkylating agent of value against both hematologic malignancies and solid tumors.
Approved
Investigational
Matched Description: … An alkylating agent of value against both hematologic malignancies and solid tumors. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management...
Approved
Investigational
Matched Description: … disease and end-of-dose motor fluctuations. ... Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase ... Opicapone was approved for use by the European Commission in June 2016 [L2339] and the FDA in April 2020 …
Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir[L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity typically associated with cidofovir therapy.[A235725,A235735] Due to its...
Approved
Investigational
Matched Iupac: … -oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)[3-(hexadecyloxy)propoxy]phosphinic acid
Matched Description: … analogue [cidofovir][L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and ... treatment of cytomegalovirus (CMV), BK Virus (BKV), adenoviruses (AdV), and Epstein-Barr virus (EBV) ... against several DNA viruses,[A235725] resulting in brincidofovir being investigated for the prevention and
Matched Categories: … Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors …
Indecainide is a rarely used antidysrhythmic. Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics.
Approved
Matched Description: … Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of …
Synthetic peptide, 32 residues long formulated as a nasal spray.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Parathyroid Hormones and Analogues ... Calcium-Regulating Hormones and Agents ... Parathyroid and Antiparathyroid Agents …
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance...
Approved
Matched Description: … [A31331] Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. ... [A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting ... binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's …
Matched Categories: … Nucleic Acid Synthesis Inhibitors ... dolutegravir and rilpivirine ... emtricitabine, tenofovir disoproxil and rilpivirine ... emtricitabine, tenofovir alafenamide and rilpivirine …
Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of...
Approved
Investigational
Matched Description: … The US and Europe approved it in 2000 and 2005, respectively.[A1379,A1383] …
Matched Categories: … Calcium-Regulating Hormones and Agents …
Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission.
Approved
Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is...
Approved
Investigational
Withdrawn
Matched Description: … Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar ... It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections. ... Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with …
Matched Categories: … Erythromycin and similars ... Macrolides, Lincosamides and Streptogramins …
Cerliponase alfa is an enzyme replacement treatment for a specific form of Batten disease. It was the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl...
Approved
Investigational
Matched Description: … treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.
Approved
Illicit
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist. According to the WHO, moxisylyte is approved since 1987 and in the same year, it acquired the denomination of orphan product by the FDA. This drug was developed by the Japanese company Fujirebio and also...
Approved
Investigational
Matched Description: … Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist ... [T45] According to the WHO, moxisylyte is approved since 1987[T91] and in the same year, it acquired ... [L1172] This drug was developed by the Japanese company Fujirebio and also by the American company Iolab …
Matched Categories: … Genito Urinary System and Sex Hormones …
The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced...
Approved
Matched Description: … The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor ... [A204155] Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts ... Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and
Matched Categories: … Genito Urinary System and Sex Hormones ... perindopril, amlodipine and indapamide ... rosuvastatin, perindopril and indapamide ... perindopril, bisoprolol, amlodipine and indapamide …
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).[A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint...
Approved
Investigational
Matched Description: … Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte ... was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and ... has garnered interest in the treatment of a variety of cancers, including leukemia[A246160] and melanoma …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide, a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal...
Approved
Matched Description: … [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from ... known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like [axicabtagene ciloleucel] and ... vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic cell and gene therapy ... Receptors, Cytoplasmic and Nuclear ... Antineoplastic and Immunomodulating Agents …
Saquinavir is an HIV-1 protease inhibitor used in combination with ritonavir and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a...
Approved
Investigational
Matched Description: … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals ... it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and ... the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and
Matched Categories: … Metabolic Side Effects of Drugs and Substances …
Displaying drugs 2126 - 2150 of 15111 in total